Evidence map›Paper›PMID 20623995›Full record

ArticleAIDS research and human retroviruses2010

Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin.

Sherri L Surman, Scott A Brown, Bart G Jones, David L Woodland, Julia L Hurwitz

Abstract read
In one paragraph

Article in AIDS research and human retroviruses, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. CD4Vaccine · 2017
    Article
  2. Article
  3. Article
  4. Respiratory syncytial virus vaccine development.Expert review of vaccines · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sherri L SurmanDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Scott A Brown
Bart G Jones
David L Woodland
Julia L Hurwitz
St. Jude Children's Research Hospital · USTrudeau Institute · USUniversity of Tennessee Health Science Center · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
SINGLE CELL ANALYSIS OF A MULTI-TIER AIDS VACCINEP01AI045142 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HURWITZ, JULIA L · 1999 to 2004
$7.0M
HIV-envelope-specific CD4+ T-cell activation and functional potentialsR01AI078819 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HURWITZ, JULIA L · 2009 to 2010
$831k
Recombinant Sendai Virus as a Novel HIV Vaccine VectorR21AI056974 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SLOBOD, KAREN S · 2003 to 2004
$450k
NCI NIH HHS P30-CA21765NIAID NIH HHS P01-AI45142NIAID NIH HHS R01-AI078819NIAID NIH HHS R21-AI056974
6 · The paper itself

Abstract

T cell-mediated viral clearance is classically attributed to the CD8(+) T cell subset, but CD4(+) T cells can sometimes assume this role. One such instance was illustrated by the immunization of C57BL/6 mice with HIV-1 envelope, followed by challenge with a recombinant Sendai virus (rSeV-env) carrying a gene for secreted HIV-1 envelope protein. Vaccinated mice that lacked both B cells (microMT) and CD8(+) T cells controlled virus, but control was lost when CD4(+) T cells were depleted. To explain this activity, we questioned whether CD4(+) T cells might utilize perforin for killing of MHC class II-positive targets. We also asked if the process might depend on IFN-gamma, which can upregulate MHC expression and enhance T cell recruitment to sites of virus challenge. To address these possibilities, we vaccinated perforin-KO mice with HIV-1 envelope and challenged them with rSeV-env. We found that perforin was not required for (1) CD4(+) T cell homing to the site of virus challenge, (2) expression of Th1 and Th2 cytokines (including IFN-gamma), or (3) virus clearance. To determine if IFN-gamma was required for protection, we repeated experiments in IFN-gamma-KO animals. In this case, significant protection was lost, although the CD4(+) T cells trafficked readily to the site of infection. In fact, local CD4(+) T cell numbers in vaccinated IFN-gamma- KO mice exceeded those in wild type animals. In both cases, cells were alphass TCR(+), NK-1.1(-), and CD44(+), typifying an activated CD4(+) T cell subset. Taken together, our results showed that HIV-1 envelope recombinant virus clearance was dependent on CD4(+) T cells and IFN-gamma, but occurred in the absence of B cells, CD8(+) T cells, or perforin.

Indexed as

AnimalsB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-Lymphocytesenv Gene Products, Human Immunodeficiency VirusFemaleGenetic VectorsHIV-1HIV InfectionsInterferon-gammaMiceMice, Inbred C57BLMice, KnockoutPerforinSendai virusenv Gene Products, Human Immunodeficiency VirusInterferon-gammaPerforin

Identifiers

PMID20623995
PMCPMC2932556
OpenAlexW2034223728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.